Group items tagged

The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimers disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimers disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicitate research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimers disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research.

The goal of this FOA is to support basic and clinical research on the influence of alcohol on susceptibility and progression of Alzheimer's disease and its related dementias. Recent longitudinal studies have provided strong evidence that alcohol use disorder is associated with the high risk of all types of dementias, and frequent heavy drinking increases risk of both Alzheimer's disease and vascular dementia. Even moderate alcohol consumption may be a risk factor for adverse brain outcomes and cognitive decline. Although these studies link heavy and frequent alcohol drinking to dementias in aging populations, mechanisms contributing to this relationship are not well understood. With this FOA, we solicit research projects that combine diverse expertise and use innovative approaches to investigate mechanisms by which alcohol affects brain aging processes to produce dementias and influences development of Alzheimer's disease. This FOA strongly encourages collaborations between alcohol researchers and experts in Alzheimer's disease and its related dementia research

The National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) intend to publish a Funding Opportunity Announcement (FOA) to solicit applications for a large prospective clinical research study to determine the specific subsets of stroke events that predict cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors and comorbidities along the AD/ADRD spectrum may causally synergize with stroke to result in (or prevent) cognitive impairment and dementia outcomes. The goals of this initiative are to determine the association between specific subsets of stroke events and subsequent cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations; to identify additional clinical factors and comorbidities that may affect these associations; and to contribute to development and validation of clinical-trial ready diagnostic and progression biomarkers for post-stroke dementia. It is expected that the study design will also allow for determination of interrelationships (cross-sectional and longitudinal) among the stroke event, overall cerebrovascular and cardiovascular disease and risk factors (including sex, racial, and ethnic differences), dementia-relevant genetic variants (including ApoE) and mutations (e.g. in Notch 3) previously associated with Alzheimer's disease (e.g. APP, PS1, PS2, PICALM, CLU, TREM2), cognitive trajectories including decline and resistance to decline, as well as amyloid and tau biomarkers of Alzheimers pathology during life.

This NOFO fulfills activities described in the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer's Act PL115-406. This announcement will fund Public Health Centers of Excellence (PHCOE) to support nationwide implementation of the 25 actions in the Healthy Brain Initiative's State and Local Public Health Partnerships to Address Dementia: The 2018-2023 Road Map (RM) [https://www.cdc.gov/aging/healthybrain/roadmap.htm] across the United States. Each PHCOE will choose one topic-specific area for their focus from the following list: Dementia Risk Reduction, Early Detection of Dementia, and Dementia Caregiving. The activities for each PHCOE will align directly with the actions identified in the RM for each topic area. Recipients will focus on identifying, translating and disseminating promising research findings and evidence-informed best practices, including those that address social determinants of health, for nationwide systematic public health uptake by state, local, tribal and other public health programs. PHCOEs will collaborate with CDC, other national partners and state, local and tribal health entities to ensure maximum impact and reach.

With one in three people having a clinical stroke during their lifetime and dementia occurring in an estimated 30% of post-stroke patients, the public health impact is enormousþff. The purpose of this FOA is to determine the specific subsets of stroke events that cause (and do not cause) cognitive impairment and dementia in post-stroke populations in the United States, including in health disparities populations, and what additional clinical factors, as well as comorbidities including those along the AD/ADRD spectrum, may causally synergize with stroke to result in cognitive impairment and dementia outcomes. Applicants are encouraged to leverage existing resources for VCID, stroke and other dementia research.    

The purpose of this FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

The purpose of this FOA is to solicit applications for the next 6-year cycle of the Health and Retirement Study (HRS), which is the leading longitudinal data resource on patterns of age-related changes in the health and well-being of adults age 50 and older in the U.S. The goals of the next cycle are to: 1) continue the current structure and design elements of the HRS while reducing respondent burden; 2) establish a repository of blood samples for future study; 3) enrich administrative linkages and collaborations with genetics consortia; 4) conduct follow-up dementia assessment using the Harmonized Cognitive Assessment Protocol (HCAP) to update data on the prevalence of dementia including Alzheimer's Disease and related dementias (AD/ADRD); 5) enhance harmonization with comparable surveys of population aging; and 6) augment data dissemination and user support. 

The purpose of the ADI-SSS program is to provide grants to public and private entities that are operating within existing, dementia-capable, long term services and supports systems and are committed to serving populations with the most need and living with or at risk of developing Alzheimer’s disease or a related dementia and their caregivers. Successful applicants will propose services designed to address the needs of each of the three service gap areas identified in the Funding Opportunity Announcement. The grantees benefit from targeted technical assistance provided by the ACL's National Alzheimer’s and Dementia Resource Center.

The Alzheimer's Drug Discovery Foundation (ADDF) is inviting applications to its Prevention Beyond the Pipeline program. Through the program, grants will be awarded in support of comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Funding priorities identified by the foundation include: Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) - Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, ADDF will support collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.

NIA's MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation's challenges posed by Alzheimer's disease and its related dementias (AD/ADRD). This FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent, e.g. DSW).

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer's disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD.

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD. Support is provided for up to 2 years of planning/development (R61 phase) of a milestone-driven infrastructure including the initial identification of top-priority research gaps and the establishment of strategies to address them. Areas identified as needing additional evidence-based research include, but are not limited to, pre-emergency department (ED) strategies to avoid non-emergency ED visits, recognition of early cognitive impairment in the ED, strategies to optimize the ED environment and providers for patients with AD/ADRD, development of safe disposition criteria, and methods to minimize system fragmentation within and across health and social services.

This initiative will provide two years of support for planning activities necessary for initiating a Phase III clinical trial designed to validate VCID biomarkers and/or treat patients with VCID. The full spectrum of VCID is in scope, and the one or more VCID disorders(s) to be targeted in the trial must be clearly specified in the application, for example (but not limited to): vascular insults including clinical stroke, silent infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), transient ischemic attack (TIA), micro-bleeds, CADASIL, and vascular contributions to Alzheimers dementia. Planning activities may include identifying trial sites/collaborations, designing trial protocols and procedures, and addressing regulatory approvals.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide clues to novel intervention targets for alleviating some of the burden associated with these symptoms, or suggest optimal prevention strategies.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviatesomeburden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD RFA-MH-19-510 uses the R01 grant mechanism, whileRFA-MH-19-511 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.